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T
he matter of immunology often 
conjures images of the minute: 
tiny cells on guard against tiny 
invaders. Many immunologists, not unrea-
sonably, think in microscopic terms—
molecular events in disease and resistance. 
Alan Aderem has likewise studied the 
infi  nitesimal. His early 
work dissected the mo-
lecular signaling path-
ways that are activated 
within macrophages 
when these white blood 
cells sense bacterial 
intruders (1, 2).
Later, Aderem’s 
view expanded some-
what. He studied the 
events that lead macro-
phages to engulf pathogens (3). He also 
became interested in a large family of 
immune cell receptors, known as the Toll 
family, that allows the host to distinguish 
between various types of pathogens (4, 5).
Now, as cofounder and director of the 
Institute for Systems Biology (ISB) in 
Seattle, WA, Aderem deals with the im-
mense. His researchers collect vast 
amounts of data on a daily basis. He now 
spends his days organizing and analyzing 
this enormous load.
MELDING WORLDS
I’ve heard you had a history of political 
involvement as a young man 
in South Africa.
I was very active in the anti-Apartheid 
movement and the African National Con-
gress. I had an active role in the trade unions 
and community movements and edited a 
township newspaper. I ended up under 
house arrest for fi  ve years and in prison.
Wow. So how did you go from activist 
to immunologist?
When I left South Africa in 1980, I tried 
to pull together my two lives: science and 
the politics of the developing world. The 
only way I could see doing that was to 
work on infectious diseases that mattered 
to people in resource-poor countries, like 
malaria and TB.
So I went to the Rockefeller Univer-
sity and worked with Zan Cohn, who 
was the macrophage maven. He con-
vinced me that infections come and go, 
but the host remains. He said I should 
work on the host response to infections 
rather than focus on any one pathogen. 
That was the best advice I ever had. For 
example, when HIV came along later, I 
was well positioned for that.
Zan was a remarkable person and an 
incredible mentor. At the time, it was a 
fantastic lab: Ralph Steinman, Gilla Kaplan, 
Sam Silverstein, Ira Mellman, Carl Nathan, 
Dan Portnoy, and others.
How did you become involved in 
systems biology?
In ’94, I started wondering what was 
going to happen when the genome was 
sequenced and how that information 
could be best used. At that time, I ran 
into Lee Hood, who was having similar 
thoughts. We came to the same conclu-
sion—that the way to go would be to 
combine biology, technology, and com-
putation. I was eager then to move to 
Seattle, where Lee had also just moved, 
so we could set up an institute that might 
do this. Together with Ruedi Aebersold, 
we cofounded the ISB in 2000.
What was so appealing about Seattle?
I was initially moving to the immunology 
department at the University of Washington, 
and they had some really good immunolo-
gists there that I wanted to interact with, 
including Sasha Rudensky, Mike Bevan, 
and Roger Perlmutter.
Seattle was also great because of its 
computational infrastructures. You had 
Microsoft and lots of young people around. 
They’d changed the world once, and they 
believed they could change it again.
Finally, I’m a serious sailor. I come from 
Capetown, where you have mountains and 
sea, and I wanted to get back to that at some 
level. They say when sailors die and go to 
heaven, they go to the Pacifi  c Northwest.
So you’re already dead?
Yes, but rigor mortis hasn’t set in.
Your original plan was to establish the 
institute at the University of 
Washington?
Yes, but for structural reasons we couldn’t 
do it there. We needed a lot of freedom to 
move, without the walls of departments. To 
do proper systems biology, you need team-
work. You need to have people with com-
plementary skills working together under 
one roof: from hardcore mathematicians, 
physicists, chemists, biologists, physicians, 
epidemiologists, ecologists, etc. And team-
work’s basically the kiss of death for an 
academic career. They’ll always say, “What 
did she do?” Not, “What did she do with 
fi  ve colleagues?”
We also needed global technologies—
robots and very big, very expensive 
machines, the kind of stuff that you can 
normally get in a company but not in a 
university. Within particular departments, 
you might have one mass spectrometer. 
But we need more than that.
And we needed to establish relation-
ships with companies. For example, our 
engineers might build a prototype of an 
instrument, but to actually build a robust 
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instrument, you need to interface with com-
panies. Those sorts of things are extremely 
diffi  cult to do in a university.
A SYSTEMS APPROACH
How would you deﬁ  ne “systems biology”?
My defi  nition is a comprehensive, quanti-
tative analysis of the manner in which all 
the components of a biological system 
interact functionally and over time.
The underlying principle is that the 
question comes from biology. And if it can’t 
be answered by the technology that’s avail-
able at the time, then the technology is 
developed. That technology can then 
revolutionize biology in general. For exam-
ple, Lee’s motivation for developing the 
DNA sequencer was to answer a question 
regarding antibody structure. But once it 
was built, it enabled the genome to be 
sequenced. Biology drives technology, 
and then technology revolutionizes biology.
The most important aspect of systems-
level analysis is that you have a shot at 
understanding emergence. Complex systems 
are not demonstrated by the individual parts, 
so they can’t be predicted even if you com-
pletely understand the parts alone. Life is 
like that. It’s not inherent in DNA and RNA 
and protein and carbohydrate and lipid. You 
can take all of those things and mix them in 
a bowl, and you don’t have life. Life’s a con-
sequence of their actions and interactions.
To identify the emergent properties of a 
biological system, you’ve got to capture an 
enormous amount of information about it, 
and you need to be able to infer its emer-
gent properties computationally.
Is immunology particularly well-suited 
for systems analysis?
I think so, yes. First, it is a system. And you 
can isolate the cells in a functional state. 
This allows you to perturb and interrogate 
them. Once you have the right tools in hand 
you can extend your investigation in vivo. 
You can’t easily do that with organs. It is 
very hard to tease the brain apart and get 
different types of cells that will communi-
cate with each other in a dish.
What are the institute's long-term goals?
I think the real societal benefi  t of systems 
biology is going to be predictive, preven-
tive, and personalized medicine.
Cure is more likely for most diseases if 
they are identifi   ed early. The predictive 
component comes from two ends. One is 
your genes: polymorphisms and mutations 
that predispose you to various diseases. The 
other is biomarkers that defi  ne your particu-
lar health status at a given time. Biomarkers 
must be multi-parameter, for example, the 
proteome of the blood or the transcriptional 
profi  le of a circulating cell.
The preventive side would be interven-
ing by changing your diet or your habits, 
or taking a drug or vaccine.
The personalized aspect would be tailor-
ing the therapy to the needs of the indi-
vidual. If you integrate someone’s genetic 
information with their health status, you 
can individualize the therapy.
And we’ve thrown in one additional 
component, which we call the fourth P, for 
participatory. If you had access to medical 
information and all your data, you could 
very much be involved in shaping your 
treatment and your health.
Do you fear any ethical issues 
associated with access to that sort of 
information?
Yes, in the sense that insurance compa-
nies would love to get a hold of that infor-
mation, for instance. But those things can 
be handled. People deal with their banks 
through the web; safeguards exist when 
you buy something on the internet; we 
can protect the information.
There are much more diffi  cult questions. 
For example, if you have an incurable 
disease is it better to know? Is it worth 
leading a constrained life, because you 
know that at some point in the future, you’re 
going to develop X disease?
LEADING THE CHARGE
What are some of the challenges you’ve 
encountered as institute director?
One diffi  culty has been to get scientifi  c 
integration among the various disciplines. 
I had initially thought that the physicists 
would understand biology rather easily, 
because they’d all 
splashed around in 
rock pools and things 
like that as kids, but 
that the biologists 
would have a terrible 
time with the mathe-
matics of physics.
But it turned out 
to be exactly the op-
posite. Because biologists are trained quan-
titatively, they can sit down and fi  gure out 
how to program a computer or do the quan-
titative sciences. But the physicists strive 
for simplicity, one equation that describes it 
all. The complication of biology, they hate 
it. The reason for that, of course, is evolu-
tion. Evolution is whatever works; there’s 
often no logic in the design. You can’t easily 
reverse-engineer something that’s evolved.
Having been politically involved yourself, 
do you recommend the same for other 
scientists?
Absolutely! Serious assaults are being made 
on science. More than half of the country 
doesn’t believe in evolution. Scientists need 
to get out there and educate people; for 
people to practice democracy, they need to 
understand the issues. You can’t vote on 
stem cells if you don’t know what a stem 
cell is. It’s all very well to sit in our ivory 
towers and say, “It’s not our business.” But 
actually it very much is our business.
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A macrophage extends ﬁ  lopodia to capture 
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